Your session is about to expire
← Back to Search
Monoclonal Antibodies
MCLA-145 for Non-Hodgkin's Lymphoma
Phase 1
Recruiting
Research Sponsored by Merus N.V.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Histologically or cytologically confirmed advanced or recurrent/metastatic solid tumors or B-cell lymphomas, that are considered non-amenable to surgery or other curative treatments or procedures (if applicable)
Measureable disease per RECIST v1.1 or Lugano Criteria
Timeline
Screening 3 weeks
Treatment Varies
Follow Up every 8 to 12 weeks until study ends, approximately 4 years
Awards & highlights
Study Summary
This trial is testing a new cancer drug to see if it is safe and effective.
Eligible Conditions
- Cancer
- Solid Tumors
- Non-Hodgkin's Lymphoma
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ every 8 to 12 weeks until study ends, approximately 4 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~every 8 to 12 weeks until study ends, approximately 4 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Number of patients with Adverse Events and Serious Adverse Events
Number of patients with Dose Limiting Toxicities
Secondary outcome measures
Area under the plasma concentration versus time curve [AUC]
Disease control rate ( DCR)
Duration of response ( DOR)
+5 moreTrial Design
1Treatment groups
Experimental Treatment
Group I: MCLA-145Experimental Treatment1 Intervention
In Part 1, the dose escalation phase, patients with advanced or recurrent/metastatic solid tumors or B-cell lymphomas will receive escalating doses of MCLA-145 ( every 2 weeks ) until MTD or RDE is reached. In Part 2, the expansion phase, participants with advanced or metastatic solid tumors will receive intravenous infusion of MCLA-145 at the recommended phase II dose every 2 weeks. The duration of each treatment cycle is 28 days
Find a Location
Who is running the clinical trial?
Merus N.V.Lead Sponsor
7 Previous Clinical Trials
1,247 Total Patients Enrolled
Incyte CorporationIndustry Sponsor
362 Previous Clinical Trials
54,970 Total Patients Enrolled
Ernesto Wasserman, MDStudy DirectorMerus N.V.
3 Previous Clinical Trials
513 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger